---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015884"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T21:04:34.981052+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics receives Nasdaq delisting notice for low stockholders' equity

## Summary
- Stockholders' equity fell below $2.5M minimum per Q3 2024 10-Q; delisting risk under Nasdaq Rule 5550(b)(1).
- Company has until December 30, 2024 to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Acquisition of Pharmagesic closed Oct 7, 2024, after the Q3 report, not reflected in equity calculation.
- No immediate effect on listing; common stock (DWTX) continues trading on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001558370-24-015884
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024015884/0001558370-24-015884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024015884/dwtx-20241115x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015884
- JSON: https://secwatch.observer/filing/0001558370-24-015884.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015884.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.